Possia

RSS

Withdrawn

This medicine's authorisation has been withdrawn

ticagrelor
MedicineHumanWithdrawn

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 3 December 2010, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Possia, (ticagrelor), which had been approved for the prevention of atherothrombotic events. The marketing authorisation holder (MAH) responsible for Possia was AstraZeneca AB. 

On 27 March 2013, the European Commission issued a decision to withdraw the marketing authorisation for Possia, following its receipt of a letter dated 20 December 2012 notifying the Commission of the MAH’s decision to voluntarily withdraw the marketing authorisation for this product for commercial reasons. Possia was not marketed in any European country. 

Pursuant to this decision, the European public assessment report for Possia is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (693.72 KB - PDF)

Ara

español (ES) (200.71 KB - PDF)

Ara

čeština (CS) (249.25 KB - PDF)

Ara

dansk (DA) (278.34 KB - PDF)

Ara

Deutsch (DE) (338.67 KB - PDF)

Ara

eesti (ET) (200.98 KB - PDF)

Ara

ελληνικά (EL) (285.03 KB - PDF)

Ara

français (FR) (263 KB - PDF)

Ara

italiano (IT) (202.23 KB - PDF)

Ara

latviešu (LV) (313.57 KB - PDF)

Ara

lietuvių (LT) (229.54 KB - PDF)

Ara

magyar (HU) (303.85 KB - PDF)

Ara

Malti (MT) (248.52 KB - PDF)

Ara

Nederlands (NL) (260.43 KB - PDF)

Ara

polski (PL) (250.23 KB - PDF)

Ara

português (PT) (201.13 KB - PDF)

Ara

română (RO) (230.06 KB - PDF)

Ara

slovenčina (SK) (307.1 KB - PDF)

Ara

slovenščina (SL) (240.57 KB - PDF)

Ara

suomi (FI) (201.24 KB - PDF)

Ara

svenska (SV) (198.69 KB - PDF)

Ara

Product information

български (BG) (1.27 MB - PDF)

Ara

español (ES) (722.27 KB - PDF)

Ara

čeština (CS) (955.11 KB - PDF)

Ara

dansk (DA) (624.97 KB - PDF)

Ara

Deutsch (DE) (718.62 KB - PDF)

Ara

eesti (ET) (734.64 KB - PDF)

Ara

ελληνικά (EL) (1.26 MB - PDF)

Ara

français (FR) (757.4 KB - PDF)

Ara

italiano (IT) (709.78 KB - PDF)

Ara

latviešu (LV) (1.05 MB - PDF)

Ara

lietuvių (LT) (760.99 KB - PDF)

Ara

magyar (HU) (959.74 KB - PDF)

Ara

Malti (MT) (868.76 KB - PDF)

Ara

Nederlands (NL) (721.11 KB - PDF)

Ara

polski (PL) (1.36 MB - PDF)

Ara

português (PT) (1.03 MB - PDF)

Ara

română (RO) (794.52 KB - PDF)

Ara

slovenčina (SK) (987.96 KB - PDF)

Ara

slovenščina (SL) (953.01 KB - PDF)

Ara

suomi (FI) (656.85 KB - PDF)

Ara

svenska (SV) (637.11 KB - PDF)

Ara

Íslenska (IS) (626.98 KB - PDF)

Ara

norsk (NO) (628.65 KB - PDF)

Ara
Latest procedure affecting product information:WS/0292
24/10/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (617.58 KB - PDF)

Ara

español (ES) (573.16 KB - PDF)

Ara

čeština (CS) (563.56 KB - PDF)

Ara

dansk (DA) (575.82 KB - PDF)

Ara

Deutsch (DE) (557.18 KB - PDF)

Ara

eesti (ET) (558 KB - PDF)

Ara

ελληνικά (EL) (954.96 KB - PDF)

Ara

français (FR) (587.04 KB - PDF)

Ara

italiano (IT) (584.58 KB - PDF)

Ara

latviešu (LV) (611.74 KB - PDF)

Ara

lietuvių (LT) (572.93 KB - PDF)

Ara

magyar (HU) (591.4 KB - PDF)

Ara

Malti (MT) (572.61 KB - PDF)

Ara

Nederlands (NL) (548.36 KB - PDF)

Ara

polski (PL) (600.78 KB - PDF)

Ara

português (PT) (574.41 KB - PDF)

Ara

română (RO) (609.93 KB - PDF)

Ara

slovenčina (SK) (569.01 KB - PDF)

Ara

slovenščina (SL) (553.5 KB - PDF)

Ara

suomi (FI) (578.65 KB - PDF)

Ara

svenska (SV) (575.55 KB - PDF)

Ara

Íslenska (IS) (549.89 KB - PDF)

Ara

norsk (NO) (586.22 KB - PDF)

Ara

Product details

Name of medicine
Possia
Active substance
ticagrelor
International non-proprietary name (INN) or common name
ticagrelor
Therapeutic area (MeSH)
  • Peripheral Vascular Diseases
  • Acute Coronary Syndrome
Anatomical therapeutic chemical (ATC) code
B01AC24

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

Authorisation details

EMA product number
EMEA/H/C/002303
Marketing authorisation holder
AstraZeneca AB

Gärtunavägen
151 85 Södertälje
Sweden

Marketing authorisation issued
03/12/2010
Withdrawal of marketing authorisation
27/03/2013
Revision
2

Assessment history

This page was last updated on

Share this page